Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Japan PGx Data Science Consortium Database: SNPs and HLA genotype data from 2994 Japanese healthy individuals for pharmacogenomics studies.
Kamitsuji S, Matsuda T, Nishimura K, Endo S, Wada C, Watanabe K, Hasegawa K, Hishigaki H, Masuda M, Kuwahara Y, Tsuritani K, Sugiura K, Kubota T, Miyoshi S, Okada K, Nakazono K, Sugaya Y, Yang W, Sawamoto T, Uchida W, Shinagawa A, Fujiwara T, Yamada H, Suematsu K, Tsutsui N, Kamatani N, Liou SY; Japan PGx Data Science Consortium (JPDSC). Kamitsuji S, et al. Among authors: sawamoto t. J Hum Genet. 2015 Jun;60(6):319-26. doi: 10.1038/jhg.2015.23. Epub 2015 Apr 9. J Hum Genet. 2015. PMID: 25855068
Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies.
Iitsuka H, Tokuno T, Amada Y, Matsushima H, Katashima M, Sawamoto T, Takusagawa S, van Gelderen M, Tanaka T, Miyahara H. Iitsuka H, et al. Among authors: sawamoto t. Clin Drug Investig. 2014 Jan;34(1):27-35. doi: 10.1007/s40261-013-0146-1. Clin Drug Investig. 2014. PMID: 24178236 Free PMC article. Clinical Trial.
Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.
Eltink C, Lee J, Schaddelee M, Zhang W, Kerbusch V, Meijer J, van Marle S, Grunenberg N, Kowalski D, Drogendijk T, Moy S, Iitsuka H, van Gelderen M, Matsushima H, Sawamoto T. Eltink C, et al. Among authors: sawamoto t. Int J Clin Pharmacol Ther. 2012 Nov;50(11):838-50. doi: 10.5414/CP201782. Int J Clin Pharmacol Ther. 2012. PMID: 22943933 Clinical Trial.
Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M, Keirns J, Kerbusch V, Moy S, Meijer J, Kowalski D, Morton R, Lasseter K, Riff D, Kupčová V, van Gelderen M. Dickinson J, et al. Among authors: sawamoto t. Clin Drug Investig. 2013 Jan;33(1):11-23. doi: 10.1007/s40261-012-0031-3. Clin Drug Investig. 2013. PMID: 23208320 Clinical Trial.
55 results